BH3-mimetics: recent developments in cancer therapy

Table 4 The single- and combined- synergizing, or resistance-inducing effects of Navitoclax on cellular apoptosis

Cancer	Cell Type	Combined	Apoptosis	Ref
AML	Primary cells	dasatinib	–	[141]
AML/ALL	Jurkat, Molt-4	wogonin	synergized	[142]
Cervical	SiHa, CaSki	A-1210477	synergized	[139]
CRC	HCT116, DLD1, SW48, HT29, HCT-8	apigenin	synergized	[143]
CRC, Liver	Huh7, HepG2, BEL7402, HCT116, DLD1, AGS	sorafenib	synergized	[144]
CRC/Melanoma	Colo-205	AZD6244 resistance	–	[145]
Esophageal	SKGT-4, KATO-TN, YES-6	fluorouracil	synergized	[146]
Esophageal	EC109, HKESC-2, CaES-17	-single-	–	[147]
HNSCC	HN12	fenretinide	synergized	[148]
Liver	Huh7	TRAIL resistance	–	[149]
Lung	H1650 and H1975	src-inhibitors	synergized	[150]
Non-small cell lung	LC2, PC10	cisplatin	synergized	[151]
Small cell lung	H209	vorinostat	synergized	[152]
Lymphoma	DoHH-2 and SuDHL-4	rapamycin	–	[153]
Neuroblastoma	SH-SY5Y and CHLA-119	norcantharidin	synergized	[154]
Prostate	LNCaP and PC3	paclitaxel	synergized	[155]
Prostate	PC3, C4–2B, C4–2, DU145	MLN2238	synergized	[156]
Ovarian	Numerous	paclitaxel/gemcitabine	synergized	[157]
Liver, Prostate, Cervical, CRC, NSCLC	Hep3B, PC3, HCT-116, SW480, and SW620, H1299, SK-BR-3, HeLa	metformin	synergized	[158]

The cancer types are highlighted in bold (left column), the evaluation of single therapy alone is highlighted by -single-, non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the column on the right (Ref). Abbreviations: AML Acute Myelogenous Leukemia, ALL Acute Lymphoblastic Lymphoma, CRC Colorectal cancer, HNSCC Head and Neck Squamous Cell Carcinoma, NSCLC Non-small cell lung cancer

ISSN: 1756-9966